1: Urology. 2003 Nov;62(5):894-9. L5 mg with placebo in 3040 men inks
Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia.Roehrborn CG, Lee M, Meehan A, Waldstreicher J; PLESS Study Group.
University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA
OBJECTIVES: To examine the effect of finasteride on serum testosterone in men with benign prostatic hyperplasia (BPH). METHODS: The Proscar Long-Term Efficacy and Safety Study (PLESS) was a 4-year trial comparing the safety and efficacy of finasteride with moderate to severe symptomatic BPH and enlarged prostates. PLESS included the prospective measurement of annual serum testosterone in a randomly selected subset of patients comprising approximately 10% of the randomized population (n = 301). RESULTS: Finasteride treatment led to a modest, but significant (P <0.001), increase relative to placebo in serum testosterone, with this increase greatest in patients who had low baseline testosterone levels. The larger testosterone increases seen in finasteride-treated patients in the lower baseline testosterone tertiles were associated with significant mean reductions relative to placebo at year 4 in body mass index (BMI), ranging from 0.6 to 0.8 kg/m2. No statistically significant between-group difference was found in BMI in the upper testosterone tertile. The sexual adverse experience profiles for finasteride and placebo were similar across the baseline testosterone cohorts examined. CONCLUSIONS: Finasteride treatment led to a generally modest increase relative to placebo in serum testosterone, with the greatest increases occurring in men with low baseline testosterone levels. The physiologic significance of these changes in men with low baseline testosterone levels is unclear, but the associated reduction in BMI is intriguing and may be related, because BMI is known to be negatively correlated with serum testosterone levels in men.
PMID: 14624915 [PubMed - indexed for MEDLINE]
Doesn’t seem to effect T really all that much according to that study. Im assuming they’d mean less than 10% of an increase because they describe the increase as “modest”. If you BMI changed while you were on finas, things might get a bit skewed.
Finas never affected my sex drive that I know of personally. I think if I spent time “worried” about it, it might have though. Perhaps as I get older 5AR inhibitors will affect my sex drive more. I’d like a tested effective topical just like anyone else, but until large controlled third party studies are done with one over a 3 to 5 year period, I’d be hesitant to really trust one. Im anxious to see what Androscience comes up with myself.